Along with Dr. Loff, Sunil Malkani, M.D., a leading vitreo-retinal surgeon and founder of Malkani Retina Center in Fort Myers, FL, will oversee the development of Retinalyze Analytics to ensure optimal clinical benefits. Using Doctors Optimal Formula's current Provider database of more than 10,000 physicians, the integration of Retinalyze Analytics into physician practices is expected to be readily marketable.In addition to AMD, Retinalyze Analytics is slated to assist in the detection of various retinal disorders, including retinal lesions and vascular diseases that include diabetic retinopathy, hypertensive retinopathy and ocular melanoma. “Early diagnosis and treatment is critical with retinal diseases, enabling patients to be treated prior to becoming symptomatic, which can significantly improve the patients prognosis. Retinalyze Analytics will provide the most advanced SVM-based interpretations to help physicians analyze these diseases and tumors, potentially months if not years sooner than previously possible,” adds Dr. Malkani. Physicians interested in learning about Retinalyze Analytics’ referral and reimbursement program may contact Howard Loff, MD at Hloffmd@doctorsoptimalformula.com. About Doctors Optimal Formula LLC Having been founded by medical doctors, Doctors Optimal Formula prides itself on providing the best, scientifically formulated nutritional supplements and anti-aging skin care available today! Focusing on maintaining and improving the health and well being of our customers, Doctors Optimal Formula has become vertically integrated to encompass all aspects of healthcare, such as Vision Care Plans, Prescription Pharmacy Plans and a physician provider network of over 10,000 physicians. For more information, visit www.DoctorsOptimalFormula.com. About Health Discovery Corporation Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com. Forward-Looking Statements
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements in relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics, computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.